SwishX has launched an innovative Agentic AI platform tailored for the pharmaceutical and medtech sectors, aiming to revolutionize sales and marketing processes through advanced artificial intelligence.
Based in Bengaluru, SwishX is targeting a contracted annual recurring revenue of $5 million and plans to acquire over 100 enterprise clients by the end of the fiscal year 2026-27. The startup has recently secured $2.2 million in seed funding to support its expansion into various emerging markets, including Latin America, Southeast Asia, and Eastern Europe. This initiative taps into a substantial $400 billion opportunity within the pharma and medtech industries, projected to grow to $770 billion by 2033.
The platform addresses significant challenges faced by pharmaceutical companies, such as a lack of real-time visibility into critical business metrics and reliance on outdated methods for decision-making. SwishX's AI-driven solutions aim to enhance revenue outcomes by up to 30% by automating workflows and providing actionable insights. For instance, the platform can autonomously analyze thousands of tenders and draft proposals in minutes, significantly streamlining operations.
According to Dushyant Sapre, Founder & CEO of SwishX, the transformation in the pharmaceutical industry will not primarily occur in laboratories but in how companies approach market execution. By leveraging AI, SwishX aims to facilitate real-time decision-making and operational efficiency, addressing the unique complexities of emerging markets.
This launch comes at a pivotal moment as the pharmaceutical industry increasingly embraces AI, with estimates suggesting a potential annual value unlock of $60–110 billion. SwishX positions itself not as a traditional CRM but as a comprehensive Agentic AI platform designed to enhance the entire life sciences value chain, from drug development to market execution.